-

04:19:06 PM

TMBR Stock News

TMBR - Timber Pharmaceuticals Inc

06/23/22 8:00 AM

AMEX : TMBR

clinical trial

Timber Pharmaceuticals Announces First Patients Enrolled in Phase 3 ASCEND Clinical Trial Evaluating TMB-001 in Congenital Ichthyosis

via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the

RHEA-AI

very positive

05/31/22 8:00 AM

AMEX : TMBR

Timber Pharmaceuticals Receives FDA Breakthrough Therapy Designation for TMB-001 for the Treatment of Congenital Ichthyosis

via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the

RHEA-AI

positive

05/12/22 4:10 PM

AMEX : TMBR

earnings

Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2022 Financial Results

Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused

RHEA-AI

very positive

04/28/22 8:00 AM

AMEX : TMBR

Timber Pharmaceuticals Announces Fast Track Designation Granted by FDA for TMB-001 in Severe Subtypes of Congenital Ichthyosis

via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical

RHEA-AI

very positive

03/31/22 5:44 PM

AMEX : TMBR

earnings

Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2021 Financial Results

Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of

RHEA-AI

very positive

03/25/22 8:00 AM

AMEX : TMBR

Timber Pharmaceuticals Announces Late-Breaking Presentation at the American Academy of Dermatology 2022 Annual Meeting

Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a

RHEA-AI

positive

02/03/22 8:00 AM

AMEX : TMBR

clinical trial

Timber Pharmaceuticals Announces Positive End-of-Phase 2 Meeting with FDA for TMB-001 in Moderate to Severe Congenital Ichthyosis

Timber Pharmaceuticals, Inc. ("Timber" or the

RHEA-AI

neutral

01/06/22 8:00 AM

AMEX : TMBR

conferences

Timber Pharmaceuticals to Present at H.C. Wainwright BioConnect Conference

Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare

RHEA-AI

neutral

11/17/21 4:18 PM

AMEX : TMBR

conferencesclinical trial

Timber Pharmaceuticals to Host Conference Call Discussing Positive Topline Results from Phase 2b CONTROL Study of Congenital Ichthyosis for Lead Asset, TMB-001

Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of

RHEA-AI

neutral

11/15/21 4:15 PM

AMEX : TMBR

earnings

Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2021 Financial Results

Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a

RHEA-AI

very positive

TMBR Data

Websitewww.timberpharma.com
Security nameTimber Pharmaceuticals Inc
Issue typecs
Sic code2834
Employees6
Tags
- Producer Manufacturing
- Miscellaneous Manufacturing
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Medicinal and Botanical Manufacturing
Address1098 Hamilton Ct
StateCalifornia
CityMenlo Park
Zip94025-1423
CountryUS
Phone16508895020

About Timber Pharmaceuticals Inc

Timber Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases. The Company's investigational therapies have proven mechanisms-of-action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing and control) and safety profiles. The Company is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI), facial angiofibromas (FAs) in tuberous sclerosis complex (TSC), and scleroderma.